FZFang Zheng

Fang Zheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fang Zheng has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Boxuan Zhou

    Department of Breast Disease Center, General Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China

    2 shared publications
  • Bao-Xin Liu

    Department of Orthopedics, The Affiliated Guangzhou Hospital of TCM of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China

    1 shared publication
  • Dong Hou

    Department of Gastrointestinal Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    1 shared publication
  • Fanghai Han

    Department of Gastrointestinal Surgery, The Affiliated Guangdong Second Provincial General Hospital of Jinan University

    1 shared publication
  • Guie Lai

    Department of Breast Surgery, the First Affiliated Hospital of Gannan Medical University, Ganzhou, China

    1 shared publication
  • Jia Zhu

    Department of Breast Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China

    1 shared publication

Latest Publications

  • Open Access

    NFYB–lncRNA axis resets the tumor microenvironment to promote HCC aggressive progression by a positive feedback loop

    by Boxuan Zhou, Qiang Tao, Wu Wen, Jianan Tan, Jie Xu, Yixuan Fang, Jiao Guan, Xiaorong Lin, Jiehua He, Milad Ashrafizadeh, et al.


  • Open Access

    Systematic analysis of anoikis-related genes identifies SRPX2-FAK/AKT-IL-6 axis in the progression and peritoneal metastasis of gastric cancer

    by Dong Hou, Jinhao Yu, Yequan Xie, Shengning Zhou, Jintao Zeng, Mingtao Liang, Fang Zheng, Jianan Tan, Fanghai Han

    Introduction: Peritoneal metastasis (PM) remains a primary cause of poor prognosis in advanced gastric cancer (GC). While anoikis resistance enables detached tumor cells to survive and promotes invasion and metastasis, its specific mechanisms in GC related PM are not yet fully understood. Methods: Anoikis related differentially expressed genes were identified using GC samples from the TCGA and GEO databases. Molecular subtypes were characterized by non negative matrix factorization (NMF) clustering. Survival outcomes were assessed via Kaplan–Meier analysis, and functional profiles were evaluated through pathway enrichment scoring. A prognostic risk model was constructed by combining weighted gene co expression network analysis (WGCNA) with Lasso–Cox regression. For PM diagnosis, characteristic genes were screened using support vector machine (SVM) and random forest (RF) algorithms to build a diagnostic model. Experimental validation was performed to confirm the expression and functional role of SRPX2. Results: GC was stratified into two molecular subtypes. Subtype A showed marked enrichment of anoikis resistance related factors and was associated with significantly poorer prognosis. A six gene prognostic signature (HEYL, SRPX2, LBH, PLAT, ITGAV, HTRA1) was established and validated externally. A nine gene diagnostic panel (SLC30A9, ZFHX4, CYTB, NDFIP2, NMNAT2, SRPX2, TBC1D8B, CLEC3B, CHRDL2) was also constructed for PM. SRPX2 was identified as an independent prognostic marker and a PM associated biomarker, highly expressed in cancer associated fibroblasts (CAFs). Functional studies demonstrated that SRPX2 promotes GC progression and peritoneal metastasis by activating the FAK/AKT pathway and IL-6 paracrine signaling, thereby inducing anoikis resistance. Discussion: This study proposes an anoikis based molecular classification of GC and develops both prognostic and diagnostic models for PM. It further reveals that SRPX2 driven anoikis resistance, mediated through the FAK/AKT-IL-6 axis, facilitates peritoneal metastasis. These findings provide new directions for prognostic assessment and therapeutic strategies in gastric cancer.


  • Open Access

    Effects of heel kicking exercise on knee pain and joint function in knee osteoarthritis: A randomized controlled trial

    by Zhanliang Tan, Jiawen Wang, Yingfeng Cai, Jianpeng Zhou, Tianzhao Tian, Weijun Zhou, Peng Huang, Pei Zhou, Jiahui Li, Fang Zheng, et al.

    Background: Exercise therapy is a core intervention for knee osteoarthritis (KOA). For KOA patients, active and passive stretching exercises can relieve joint pain and restore joint function. Heel kicking exercise (HKE) is a dynamic stretching method designed by the authors to rapidly reduce knee pain and restore joint function in patients with KOA. This randomized controlled trial was conducted to determine the efficacy of HKE for pain and joint function in patients with KOA. Method: A total of 68 patients with KOA were included in this study. Eight patients were excluded, resulting in random allocation into a control group (N = 29, 1 lost to follow-up) and an observation group (N = 30). Both groups received traditional Chinese medicine hot compress therapy, oral administration of celecoxib capsules, and quadriceps contraction exercises. The control group additionally performed static stretching exercises targeting the quadriceps, hamstrings, and gastrocnemius muscles; conversely, the observation group performed in HKE. Changes in Western Ontario and McMaster Universities Osteoarthritis Index pain and stiffness indices, knee joint range of motion, Five-Times-Sit-to-Stand Test, Timed Up and Go Test, and Six-Minute Walk Test were assessed before treatment initiation and after 2 weeks. Results: Before treatment, there were no significant differences in the Western Ontario and McMaster Universities Osteoarthritis Index pain and stiffness score, joint range of motion, Five-Times-Sit-to-Stand Test, Timed Up and Go Test, and Six-Minute Walk Test levels between the 2 groups (P > .05). After treatment, the observation group outperformed the control group across all indicators (P < .05, P < .01). Patients’ satisfaction within 2 groups were investigated, which showed that patients’ satisfaction within the observation group were better than those in the control group (P < .01). Conclusions: HKE is an effective and safe exercise therapy that significantly alleviates knee pain in patients with KOA while restoring joint function.

  • Open Access

    Targeting tumor exosomal circular RNA cSERPINE2 suppresses breast cancer progression by modulating MALT1-NF-𝜅B-IL-6 axis of tumor-associated macrophages

    by Boxuan Zhou, Zhaohong Mo, Guie Lai, Xiaohong Chen, Ruixi Li, Runxin Wu, Jia Zhu, Fang Zheng

    Background: Circular RNAs (circRNAs) have important regulatory functions in cancer, but the role of circRNAs in the tumor microenvironment (TME) remains unclear. Moreover, we also explore the effects of si-circRNAs loaded in nanoparticles as therapeutic agent for anti-tumor in vivo. Methods: We conducted bioinformatics analysis, qRT-PCR, EdU assays, Transwell assays, co-culture system and multiple orthotopic xenograft models to investigate the expression and function of circRNAs. Additionally, PLGA-based nanoparticles loaded with si-circRNAs were used to evaluate the potential of nanotherapeutic strategy in anti-tumor response. Results: We identified oncogene SERPINE2 derived circRNA, named as cSERPINE2, which was notably elevated in breast cancer and was closely related to poor clinical outcome. Functionally, tumor exosomal cSERPINE2 was shuttled to tumor associated macrophages (TAMs) and enhanced the secretion of Interleukin-6 (IL-6), leading to increased proliferation and invasion of breast cancer cells. Furthermore, IL-6 in turn increased the EIF4A3 and CCL2 levels within tumor cells in a positive feedback mechanism, further enhancing tumor cSERPINE2 biogenesis and promoting the recruitment of TAMs. More importantly, we developed a PLGA-based nanoparticle loaded with si-cSERPINE2, which effectively attenuated breast cancer progression in vivo. Conclusions: Our study illustrates a novel mechanism that tumor exosomal cSERPINE2 mediates a positive feedback loop between tumor cells and TAMs to promote cancer progression, which may serve as a promising nanotherapeutic strategy for the treatment of breast cancer.